Press Releases

Newsroom
In the News
Press Releases
Resources for Journalists

Press Releases

Share
Share
and/or
509 News Releases found
Novel Genetic Mutation that Causes the Most Common form of Eye Cancer Discovered

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.
Media Advisory
Genetic Variants May Affect the Risk of Breast Cancer in Women with BRCA2 Mutations

An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with <i>BRCA2</i> mutations that may increase or decrease their risk of developing breast cancer.
Moshe Shike
New Way of Expanding Cancer Screening for Minority Women

Minority patients have a significantly decreased survival from colon cancer compared to white patients, most often as a result of a late diagnosis. To help address this problem, a team of healthcare professionals at Memorial Sloan Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist.
Pictured: Eric C. Holland
Researchers Discover Genetic Changes That Make Some Forms of Brain Cancer More Aggressive Than Others

A multi-institutional team led by investigators from Memorial Sloan Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies.
Media Advisory
Blood Test Accurately Predicts Death from Prostate Cancer up to 25 Years in Advance

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the <i>British Medical Journal</i>.
The Brooklyn Infusion Center offers leading-edge chemotherapy services in a serene and welcoming environment.
Innovative Outpatient Chemotherapy Center to Open in Brooklyn

Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn - which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.
Paul Chapman
New Targeted Therapy for Advanced Melanoma Associated with 80 Percent Response Rate

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the <i>New England Journal of Medicine</i>.
Craig B. Thompson, MD
Craig Thompson Named President of Memorial Sloan Kettering Cancer Center

Craig B. Thompson, MD, has been named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center effective November 2, 2010. His appointment concludes a search that began in January 2010.
Newly Developed Prediction Tool Helps Estimate Local Recurrence in Patients with Non-invasive Breast Cancer

The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. In an attempt to help physicians and patients weigh the risks and benefits of the available options, researchers from Memorial Sloan Kettering Cancer Center (MSKCC) are reporting in the <I>Journal of Clinical Oncology</I> on the development of a new prediction tool that calculates a patient's individualized risk for recurrence five and ten years after surgery.
Memorial Sloan Kettering's Center for Image Guided Intervention has two devices for performing CT angiography to visualize and plan treatments.
New Cancer Diagnostic and Treatment Facility Opens

Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.